[Itraconazole in the treatment of Candida vulvovaginitis in patients with type II diabetes mellitus (non-insulin dependent)].
The purpose of this study was to know the utility of traditional administration of itraconazole to vulvovaginitis by Candida in patients with diabetes mellitus. A randomized, single blind, controlled clinical assay, was carried out in 32 patients with diabetes mellitus type II and vulvovaginitis for Candida albicans. A study group was formed with 16 patients. They received 200 mg/day of itraconazole with breakfast for 3 days. The other 16 women were the control group. A good clinical response was obtained in 87.50% of the patients (p = 0.001). Candida disappeared in 56.25% of the cases. General response showed medication failure in 43.75%. It is concluded that the traditional treatment of itraconazole for vulvovaginitis for Candida albicans in women with diabetes mellitus is a good choice to control the signs and symptoms, but it doesn't erradicate the fungus.
González Ortiz
M
M
Departamento de Medicina, Hospital General Regional No. 45, IMSS, Guadalajara, Jalisco.
Martínez Abundis
E
E
D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000150:complications / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008875:Middle Aged; D016037:Single-Blind Method
D017964:Itraconazole
Itraconazol como tratamiento de vulvovaginitis por Candida en pacientes con diabetes mellitus tipo II (no insulino-dependiente).